RESUMO
Bi-doped glasses and optical fibers are extensively studied since they present broadband optical amplification in the near-infrared region (NIR), in which the optical telecommunication industry greatly depends for the transmission of optical signals. There are many scientific challenges about the NIR luminescent emissions from Bi ions, such as understanding its origin and further improving the associated optical amplification capacity. In this work, Bi-doped germanosilicate glass compositions with ultrabroadband NIR luminescence were fabricated, in the range of 925-1630 nm, which covers O, E, S, C, and L-telecommunication bands. An in-depth analysis of the impact of modifying excitation wavelengths, Bi content, and GeO2/SiO2 concentration ratio in the glass matrix demonstrates the possibility of considerably manipulating the Bi NIR luminescence, in terms of tuning emission parameters such as bandwidth, up to ~ 490 nm, and luminescence intensity. Based on theoretical and experimental luminescence data retrieved from the fabricated glasses, we demonstrate that the origin of broadband luminescence under all the considered excitation wavelengths can be ascribed to optical transitions of Bi0 ions. Therefore, an energy level diagram for Bi0 is proposed. We anticipate that our findings can provide clarifications to the existing uncertainty in the origin of Bi NIR emission, which will be useful to fabricate efficient future optical fiber amplifiers.
RESUMO
BACKGROUND: Congenital hypothyroidism (CH) is most common preventable cause of mental retardation in children. Cord blood Thyroid Stimulating Hormone (CBTSH) level is an accepted screening tool for CH. OBJECTIVES: To study CBTSH profile in neonates born at tertiary care referral center and to analyze the influence of maternal and neonatal factors on their levels. DESIGN: Cross retrospective sectional study. METHODS: Study population included 979 neonates (males = 506 to females = 473). The CBTSH levels were estimated using electrochemiluminescence immunoassay on Cobas analyzer. Kit based cut-offs of TSH level were used for analysis. All neonates with abnormal CBSTH levels, were started on levothyroxine supplementation 10 µg/Kg/day and TSH levels were reassessed as per departmental protocol. RESULTS: The mean CBTSH was 7.82 µIU/mL (Range 0.112 to 81.4, SD = 5.48). The mean CBTSH level was significantly higher in first order neonates, neonates delivered by assisted vaginal delivery and normal delivery, delivered at term or preterm, neonates with APGAR score <5 and those needing advanced resuscitation after birth. The CBTSH level >16.10 and <1.0 µIU/mL was found in 4.39 % and 1.02 % neonates respectively. The prevalence rate of CBTSH level >16.1 µIU/mL was significantly higher in neonates delivered by assisted vaginal delivery and normal delivery, term and preterm neonates, APAGR score of <5, presence of fetal distress, need for resuscitation beyond initial steps and in those with birth weight of <1.5 Kg. Three neonates were confirmed to have CH after retesting of TSH level. CONCLUSIONS: The CBTSH estimation is an easy, non-invasive method for screening for CH. The cutoff level of CB TSH (µIU/mL) >16.10 and <1.0 led to a recall of 5.41% of neonates which is practicable given the scenario in our Country. The mode of delivery and perinatal stress factors have a significant impact on CBTSH levels and any rise to be seen in the light of these factors. The prevalence rate of CH after recall was ~3 in 1000 live births.